US probes J&J on recalled hip implant marketing (Update)

February 22, 2013 by Linda A. Johnson

(AP)—U.S. prosecutors are investigating Johnson & Johnson's practices in marketing a line of hip replacements recalled in 2010 because many had to be replaced within a few years—part of a string of more than 30 product recalls by the health care giant in the last 3 1/2 years.

The U.S. Attorney's Office in Massachusetts and the Civil Division of the U.S. Justice Department last August sent Johnson & Johnson an "informal request" for information about its ASR hip replacements, J&J reported in a regulatory filing Friday.

Just last week, Johnson & Johnson issued a recall on a different line of its hip implants, the "Adept" brand all-metal total hip replacement system, also because a higher-than-expected percentage of one part of them had to be replaced.

A patient registry in the United Kingdom found about 12 percent of people who had gotten those joints needed them replaced within seven years. In Australia, a registry showed 7 percent of patients needed replacements in just three years.

The company's annual report to the U.S. Securities and Exchange Commission states that the government has asked for additional documents from DePuy Synthes and two related subsidiaries. They have turned over the documents and are cooperating fully with investigators, the filing states.

DePuy Synthes is one of the world's biggest makers of joint replacements, surgical trauma equipment and other orthopedic surgery products.

The filing didn't specify what the government is looking for, but J&J has had legal problems before over its artificial joints. Just days before the ASR systems were recalled, the Food and Drug Administration told DePuy to stop marketing its Corail Hip System for two unapproved uses.

And in 2007, J&J agreed to pay $84.7 million in fines as part of a settlement of a sweeping investigation by the Justice Department into alleged kickbacks. J&J and the four other top U.S. makers of replacement hips and knees were accused of paying surgeons to get them to use their products exclusively, from at least 2002 through 2006.

DePuy recalled two artificial joint systems—the ASR Hip Resurfacing System and the ASR XL Acetabular System—in August 2010 because of unexpectedly high rates of failure. That means they caused pain and difficulty walking because they no longer fit perfectly, or that tiny pieces of metal had flaked off inside the patient's body, allegedly causing immune system problems in some people. More than 90,000 of systems were recalled in the U.S. and other countries.

That was part of an embarrassing spate of J&J recalls of artificial joints, contact lenses, prescription drugs and over-the-counter medicines that began in September 2009. Reasons range from contamination with bacteria and incorrect levels of a drug's active ingredient to a nauseating smell on containers and liquid medicines that may contain tiny metal shavings.

Lost product sales and expensive, ongoing factory upgrades have cost the company, based in New Brunswick, New Jersey, well over $1 billion.

Artificial joint systems, made of high-tech metals, plastics or ceramic, replace deteriorated joints causing severe pain and limiting mobility, usually in older folks with advanced arthritis. Hip replacement parts include the top of the thigh bone, the ball atop that and a plate lining the hip socket.

They're generally expected to last at least 10 to 20 years. In the case of the recalled DePuy ASR hip systems, one in eight patients needed theirs replaced within five years.

Attorneys representing patients needing replacements have alleged Johnson & Johnson knew about the problems with the DePuy hip systems back in 2008, but didn't stop selling them until 2009 and didn't recall the remaining products until 2010. The company has denied that and said it acted properly. It has set aside about $1 billion to cover costs of the recall and lawsuits.

Last month, the first trial began among thousands of lawsuits brought by people accusing J&J of knowingly selling faulty implants. The fraud and negligence case, brought by a former prison guard, is being heard by a jury in Los Angeles.

Artificial hips and knees from multiple manufacturers have been recalled for various problems in recent years.

J&J said it was recalling all 7,500 Adept implants shipped worldwide between 2004 and September 2011. Most likely were already implanted in patients, who were told to contact their doctor if they had problems.

In trading Friday, J&J shares fell 62 cents to $76.25.

______

Linda A. Johnson can be followed at twitter.com/LindaJ_onPharma.

Explore further: Report: J&J recalls thousands of hip implants

shares

Related Stories

Report: J&J recalls thousands of hip implants

February 14, 2013
(AP)—A German newspaper reports that Johnson & Johnson is recalling thousands of hip implants 2 1/2 years after a similar recall.

UK says metal hip replacements more troublesome

September 16, 2011
(AP) -- People who get metal hip replacements are more likely to need a replacement compared to those who get a traditional plastic one, according to a new report from a large British registry.

'Hundreds of thousands' fitted with suspect hip implants

February 28, 2012
Hundreds of thousands of people have been fitted with replacement hips whose flawed design may be exposing them to toxic metal, according to a probe by the BBC and the British Medical Journal (BMJ) unveiled Tuesday.

Ark. judge affirms $181 million in legal fees

February 1, 2013
(AP)—An Arkansas judge says Johnson & Johnson must pay $181 million in fees to attorneys who successfully argued that the pharmaceutical company committed Medicaid fraud in the marketing of its antipsychotic drug Risperdal.

Report: J&J will pay $2.2B in Risperdal settlement

July 20, 2012
(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.